Galantamine-Curcumin Hybrids as Dual-Site Binding Acetylcholinesterase Inhibitors

Galantamine (GAL) and curcumin (CU) are alkaloids used to improve symptomatically neurodegenerative conditions like Alzheimer’s disease (AD). GAL acts mainly as an inhibitor of the enzyme acetylcholinesterase (AChE). CU binds to amyloid-beta (Aβ) oligomers and inhibits the formation of Aβ plaques. Here, we combine GAL core with CU fragments and design a combinatorial library of GAL-CU hybrids as dual-site binding AChE inhibitors. The designed hybrids are screened for optimal ADME properties and BBB permeability and docked on AChE. The 14 best performing compounds are synthesized and tested in vitro for neurotoxicity and anti-AChE activity. Five of them are less toxic than GAL and CU and show activities between 41 and 186 times higher than GAL.

[1]  I. Doytchinova,et al.  Docking‐based design and synthesis of galantamine–camphane hybrids as inhibitors of acetylcholinesterase , 2017, Chemical biology & drug design.

[2]  W. Fu,et al.  Drug candidates in clinical trials for Alzheimer’s disease , 2017, Journal of Biomedical Science.

[3]  M. Ravikanth,et al.  Synthesis and Properties of Covalently Linked AzaBODIPY-BODIPY Dyads and AzaBODIPY-(BODIPY)2 Triads. , 2017, The Journal of organic chemistry.

[4]  Z. Zhivkova.  Quantitative Structure - Pharmacokinetic Relationships for Plasma Clearance of Basic Drugs with Consideration of the Major Elimination Pathway. , 2017, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[5]  I. Doytchinova,et al.  Docking‐based Design of Galantamine Derivatives with Dual‐site Binding to Acetylcholinesterase , 2016, Molecular informatics.

[6]  Vincent Zoete,et al.  A BOILED‐Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules , 2016, ChemMedChem.

[7]  Manjinder Singh,et al.  Hybrids: a new paradigm to treat Alzheimer’s disease , 2016, Molecular Diversity.

[8]  K. Kuča,et al.  7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimer’s Disease Treatment , 2015, Molecules.

[9]  I. Doytchinova,et al.  Quantitative Structure - Pharmacokinetics Relationships Analysis of Basic Drugs: Volume of Distribution. , 2015, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[10]  I. Doytchinova,et al.  Galantamine derivatives with indole moiety: Docking, design, synthesis and acetylcholinesterase inhibitory activity. , 2015, Bioorganic & medicinal chemistry.

[11]  I. Doytchinova,et al.  Molecular Docking Study on Galantamine Derivatives as Cholinesterase Inhibitors , 2015, Molecular informatics.

[12]  J. Kos,et al.  Development of multifunctional, heterodimeric isoindoline-1,3-dione derivatives as cholinesterase and β-amyloid aggregation inhibitors with neuroprotective properties. , 2015, European journal of medicinal chemistry.

[13]  C. Stevens,et al.  Further studies on anti-invasive chemotypes: An excursion from chalcones to curcuminoids. , 2015, Bioorganic & medicinal chemistry letters.

[14]  M. Tiwari,et al.  Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease. , 2015, Bioorganic & medicinal chemistry.

[15]  Katarina Nikolic,et al.  Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids , 2014, Drug design, development and therapy.

[16]  V. Andrisano,et al.  Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects. , 2014, Journal of medicinal chemistry.

[17]  M. Reale,et al.  Cholinergic system dysfunction and neurodegenerative diseases: cause or effect? , 2014, CNS & neurological disorders drug targets.

[18]  Li Wang,et al.  Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. , 2014, European journal of medicinal chemistry.

[19]  Haibin Liu,et al.  AlzPlatform: An Alzheimer’s Disease Domain-Specific Chemogenomics Knowledgebase for Polypharmacology and Target Identification Research , 2014, J. Chem. Inf. Model..

[20]  M. Rudolph,et al.  Structures of human acetylcholinesterase in complex with pharmacologically important ligands. , 2012, Journal of medicinal chemistry.

[21]  C. Theoduloz,et al.  Wild Argentinian Amaryllidaceae, a New Renewable Source of the Acetylcholinesterase Inhibitor Galanthamine and Other Alkaloids , 2012, Molecules.

[22]  Luca Goldoni,et al.  Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. , 2012, Journal of medicinal chemistry.

[23]  L. Chew,et al.  The effect of curcumin on the stability of Aβ dimers. , 2012, The journal of physical chemistry. B.

[24]  R. Orlando,et al.  A Chemical Analog of Curcumin as an Improved Inhibitor of Amyloid Abeta Oligomerization , 2012, PloS one.

[25]  Irene Bolea,et al.  Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. , 2011, Journal of medicinal chemistry.

[26]  Kazuyuki Takeda,et al.  Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid β-protein fibrils. , 2011, Bioorganic & medicinal chemistry.

[27]  Adrian Whitty,et al.  Growing PAINS in academic drug discovery. , 2011, Future medicinal chemistry.

[28]  Chao Ma,et al.  Ligand Classifier of Adaptively Boosting Ensemble Decision Stumps (LiCABEDS) and Its Application on Modeling Ligand Functionality for 5HT-Subtype GPCR Families , 2011, J. Chem. Inf. Model..

[29]  P. Kristian,et al.  Neuroactive Multifunctional Tacrine Congeners with Cholinesterase, Anti-Amyloid Aggregation and Neuroprotective Properties , 2011, Pharmaceuticals.

[30]  K. Takata,et al.  Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors* , 2010, The Journal of Biological Chemistry.

[31]  Amedeo Caflisch,et al.  Complete Phenotypic Recovery of an Alzheimer's Disease Model by a Quinone-Tryptophan Hybrid Aggregation Inhibitor , 2010, PloS one.

[32]  C. Bartolucci,et al.  Probing Torpedo californica acetylcholinesterase catalytic gorge with two novel bis-functional galanthamine derivatives. , 2010, Journal of medicinal chemistry.

[33]  Z. Ge,et al.  A novel and efficient direct aldol condensation from ketones and aromatic aldehydes catalyzed by proline–TEA through a new pathway , 2009 .

[34]  Qiaojun He,et al.  Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors. , 2009, European journal of medicinal chemistry.

[35]  T. Ahmed,et al.  Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease , 2009, Pharmacology Biochemistry and Behavior.

[36]  H. Broughton,et al.  Organocatalytic Synthesis of an Alkyltetrahydropyran , 2009 .

[37]  Franco Lombardo,et al.  Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds , 2008, Drug Metabolism and Disposition.

[38]  L. Serpell,et al.  Amyloid fibrils , 2008, Prion.

[39]  N. Inestrosa,et al.  Amyloid–cholinesterase interactions , 2008, The FEBS journal.

[40]  Taravat Ghafourian,et al.  QSPR models for the prediction of apparent volume of distribution. , 2006, International journal of pharmaceutics.

[41]  K. Balasubramanian.  Molecular orbital basis for yellow curry spice curcumin's prevention of Alzheimer's disease. , 2006, Journal of agricultural and food chemistry.

[42]  Franco Lombardo,et al.  A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. , 2006, Journal of medicinal chemistry.

[43]  D. Ferdinandov,et al.  In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands , 2006, Archives of Toxicology.

[44]  M. Cronin,et al.  Quantitative structure‐pharmacokinetic relationship modelling: apparent volume of distribution , 2004, The Journal of pharmacy and pharmacology.

[45]  S. Wonnacott,et al.  The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. , 2003, Molecular pharmacology.

[46]  C. Guillou,et al.  Synthesis and structure-activity relationships of open D-Ring galanthamine analogues. , 2003, Bioorganic & medicinal chemistry letters.

[47]  A. Cavalli,et al.  3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. , 2003, Journal of medicinal chemistry.

[48]  Martin K. Bayliss,et al.  Pharmacokinetics and Metabolism in Drug Design , 2002 .

[49]  U. Jordis,et al.  Synthesis of (±)-6H-benzofuro[3a,3,2,ef][3]benzazepine: an unnatural analog of (−)-galanthamine , 2002 .

[50]  R. Campbell,et al.  N-acyl-L-phenylalanine derivatives as potent VLA-4 antagonists that mimic a cyclic peptide conformation. , 2002, Bioorganic & medicinal chemistry letters.

[51]  U. Jordis,et al.  12H-[2]-Benzothiepino[6,5a,5-bc]benzofuran: Synthesis of a Sulfur-Analog of Galanthamine , 2001 .

[52]  M. A. Heuft,et al.  Solvent Effects on the Monobromination of α,ω-Diols: A Convenient Preparation of ω-Bromoalkanols , 2000 .

[53]  C. Guillou,et al.  Potent acetylcholinesterase inhibitors: design, synthesis and structure-activity relationships of alkylene linked bis-galanthamine and galanthamine-galanthaminium salts. , 2000, Bioorganic & medicinal chemistry letters.

[54]  C. Guillou,et al.  Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. , 1998, Bioorganic & medicinal chemistry.

[55]  Madeleine M. Joullié,et al.  Chemical and pharmacological characterization of galanthamine, an acetylcholinesterase inhibitor, and its derivatives. A potential application in Alzheimer's disease? , 1992 .

[56]  G. H. Kulkarni,et al.  A Novel Approach to the Synthesis of 7(Z), 11(Z)-Nonacosadiene, Pheromone of Drosophila Melano Gaster and 9(Z)-Tricosene, Pheromone of Musca Domestica , 1989 .

[57]  B. Condon,et al.  A convenient procedure for the monosilylation of symmetric 1,n-diols , 1986 .

[58]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[59]  L. Basile.  Virtual Screening in the Search of New and Potent Anti-Alzheimer Agents , 2018 .

[60]  Z. Zhivkova.  QUANTITATIVE STRUCTURE – PHARMACOKINETICS RELATIONSHIP FOR THE STEADY STATE VOLUME OF DISTRIBUTION OF BASIC AND NEUTRAL DRUGS * , 2018 .

[61]  Z. Zhivkova,et al.  Quantitative Structure - Pharmacokinetics Relationships for Plasma Protein Binding of Basic Drugs. , 2017, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[62]  M. Rosales-Hernández,et al.  Design of multi-target compounds as AChE, BACE1, and amyloid-β(1-42) oligomerization inhibitors: in silico and in vitro studies. , 2014, Journal of Alzheimer's disease : JAD.

[63]  Rabbat,et al.  Solvent effects on the monobromination of alpha,omega-diols: A convenient preparation of omega-bromoalkanols , 2000, The Journal of organic chemistry.

[64]  G. M. Bores,et al.  GALANTHAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE , 1996 .